Adamax ADA
Semax analogue (reported)
Reported synthetic derivative of Semax with modified termini; no published pharmacology was located, so its research profile is limited.
Evidence level. Little or no public data, or the exact identity is still being confirmed. About the badges
- Class
- Semax analogue (reported)
- Category
- Neuro, Cognitive & Sleep
- Type
- Single compound
- Abbreviation
- ADA
- Development and regulatory status
- Not approved; designer Semax analogue, no published studies found
What researchers study
Reported synthetic derivative of Semax (listed as Ac-MEHFPGPAG-NH2) with N- and C-terminal modifications described as borrowed from peptide P021, including a bulky cage group. Its pharmacology has not been described in published studies located.
Research areas
- Structure-activity comparison with Semax
- Nootropic hypotheses, untested in published work
- Analytical identification of designer peptides
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- review
No pharmacological or clinical studies of Adamax were found in the sources retrieved
- review
Regulators have identified it as a designer drug, and a 2025 New Zealand Medsafe submission proposed prescription-medicine classification
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- SemaxParent peptide, since Adamax is described as a Semax analogue
- P21 (P021)Its terminal modifications are described as borrowed from P021
